Boundless Bio, Inc. (BOLD)
D
Pipeline Grade
Financial Position (from SEC Filings)
$18.0M
Cash & Equivalents
$15.0M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$33M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07408089 | Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer | PHASE1 | Recruiting | 96 |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With ... | PHASE1 | Active Not Recruiting | 85 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.